P2RY11
Basic information
Region (hg38): 19:10111693-10115372
Links
Phenotypes
GenCC
Source: 
ClinVar
This is a list of variants' phenotypes submitted to 
- not_provided (23 variants)
- not_specified (12 variants)
- PPAN-P2RY11-related_disorder (8 variants)
- P2RY11-related_disorder (5 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the P2RY11 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000002566.5. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum | 
|---|---|---|---|---|---|---|
| synonymous | 27 | 33 | ||||
| missense | 11 | |||||
| nonsense | 1 | |||||
| start loss | 0 | |||||
| frameshift | 0 | |||||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 0 | 0 | 4 | 32 | 9 | 
GnomAD
Source: 
| Gene | Type | Bio Type | Transcript | Coding Exons | Length | 
|---|---|---|---|---|---|
| P2RY11 | protein_coding | protein_coding | ENST00000321826 | 2 | 3835 | 
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p | 
|---|---|---|---|---|---|---|
| 0.00771 | 0.566 | 124566 | 0 | 11 | 124577 | 0.0000442 | 
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | -1.47 | 323 | 257 | 1.26 | 0.0000178 | 2329 | 
| Missense in Polyphen | 95 | 79.025 | 1.2021 | 835 | ||
| Synonymous | -3.82 | 176 | 122 | 1.44 | 0.00000914 | 830 | 
| Loss of Function | 0.150 | 3 | 3.29 | 0.911 | 1.41e-7 | 32 | 
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p | 
|---|---|---|
| African & African-American | 0.0000871 | 0.0000871 | 
| Ashkenazi Jewish | 0.00 | 0.00 | 
| East Asian | 0.00 | 0.00 | 
| Finnish | 0.00 | 0.00 | 
| European (Non-Finnish) | 0.0000451 | 0.0000449 | 
| Middle Eastern | 0.00 | 0.00 | 
| South Asian | 0.0000654 | 0.0000653 | 
| Other | 0.000164 | 0.000163 | 
dbNSFP
Source: 
- Function
- FUNCTION: Receptor for ATP and ADP coupled to G-proteins that activate both phosphatidylinositol-calcium and adenylyl cyclase second messenger systems. Not activated by UTP or UDP.;
- Pathway
- Neuroactive ligand-receptor interaction - Homo sapiens (human);GPCRs, Other;GPCRs, Class A Rhodopsin-like;Signaling by GPCR;Signal Transduction;P2Y receptors;G alpha (s) signalling events;Nucleotide-like (purinergic) receptors;Class A/1 (Rhodopsin-like receptors);GPCR ligand binding;G alpha (q) signalling events;GPCR downstream signalling (Consensus) 
Recessive Scores
- pRec
- 0.135
Intolerance Scores
- loftool
- 0.708
- rvis_EVS
- 0.3
- rvis_percentile_EVS
- 71.68
Haploinsufficiency Scores
- pHI
- hipred
- N
- hipred_score
- 0.146
- ghis
- 0.532
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.539
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium | 
| Primary Immunodeficiency | Medium | Medium | Medium | 
| Cancer | Medium | Medium | Medium | 
Gene ontology
- Biological process
- adenosine receptor signaling pathway;defense response;G protein-coupled receptor signaling pathway;activation of adenylate cyclase activity;phospholipase C-activating G protein-coupled receptor signaling pathway;calcium-mediated signaling;neuronal signal transduction;G protein-coupled purinergic nucleotide receptor signaling pathway;cellular response to ATP
- Cellular component
- plasma membrane;integral component of plasma membrane
- Molecular function
- neurotransmitter receptor activity;signaling receptor activity;G protein-coupled purinergic nucleotide receptor activity;ATP-activated adenosine receptor activity